Comparing MEI Pharma (MEIP) & Its Peers

MEI Pharma (NASDAQ: MEIP) is one of 287 publicly-traded companies in the “Bio Therapeutic Drugs” industry, but how does it compare to its rivals? We will compare MEI Pharma to similar businesses based on the strength of its valuation, profitability, earnings, dividends, risk, analyst recommendations and institutional ownership.

Profitability

This table compares MEI Pharma and its rivals’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
MEI Pharma -8.24% -3.62% -3.33%
MEI Pharma Competitors -5,441.68% -162.70% -35.92%

Risk & Volatility

MEI Pharma has a beta of 1.83, indicating that its stock price is 83% more volatile than the S&P 500. Comparatively, MEI Pharma’s rivals have a beta of 2.42, indicating that their average stock price is 142% more volatile than the S&P 500.

Analyst Recommendations

This is a summary of current ratings for MEI Pharma and its rivals, as provided by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
MEI Pharma 0 0 2 0 3.00
MEI Pharma Competitors 925 3348 11860 238 2.70

MEI Pharma currently has a consensus target price of $6.75, suggesting a potential upside of 209.63%. As a group, “Bio Therapeutic Drugs” companies have a potential upside of 41.52%. Given MEI Pharma’s stronger consensus rating and higher probable upside, equities analysts plainly believe MEI Pharma is more favorable than its rivals.

Institutional and Insider Ownership

23.2% of MEI Pharma shares are held by institutional investors. Comparatively, 49.7% of shares of all “Bio Therapeutic Drugs” companies are held by institutional investors. 5.3% of MEI Pharma shares are held by company insiders. Comparatively, 17.5% of shares of all “Bio Therapeutic Drugs” companies are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Earnings and Valuation

This table compares MEI Pharma and its rivals top-line revenue, earnings per share and valuation.

Gross Revenue Net Income Price/Earnings Ratio
MEI Pharma $23.25 million $2.67 million -43.60
MEI Pharma Competitors $290.27 million $35.99 million 54.46

MEI Pharma’s rivals have higher revenue and earnings than MEI Pharma. MEI Pharma is trading at a lower price-to-earnings ratio than its rivals, indicating that it is currently more affordable than other companies in its industry.

Summary

MEI Pharma rivals beat MEI Pharma on 7 of the 13 factors compared.

About MEI Pharma

MEI Pharma, Inc. is an oncology company. The Company is focused on the clinical development of drugs and therapies for treatment of cancer. The Company’s portfolio of clinical drug candidates includes Pracinostat, ME-344 and PWT143. Pracinostat is an orally available histone deacetylase (HDAC) inhibitor indicated for the treatment of advanced hematologic diseases, such as acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS). ME-344 is an isoflavone-based mitochondrial inhibitor targeting a mitochondrial component of the terminal respiratory chain complex in rapidly proliferating cells. PWT143 is an oral inhibitor of phosphatidylinositide 3-kinase (PI3K) delta, a molecular target that plays a critical role in the proliferation and survival of hematologic cancer cells. Pracinostat has been tested in multiple Phase I and Phase II clinical trials in advanced hematologic malignancies and solid tumor indications.

Receive News & Ratings for MEI Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MEI Pharma and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

How to Trade on Forex – 8 Steps for Beginners
How to Trade on Forex – 8 Steps for Beginners
Super Nintendo World Theme Park Officially Starts Construction
Super Nintendo World Theme Park Officially Starts Construction
Amazon and Apple Join Foxconn to Secure Chip Business of Toshiba
Amazon and Apple Join Foxconn to Secure Chip Business of Toshiba
Camera Zooms In and Can Recognize Faces
Camera Zooms In and Can Recognize Faces
Netflix Could See 150 Million Worldwide Subscribers
Netflix Could See 150 Million Worldwide Subscribers
LeEco Cutting Over 70% of Staff in U.S. Amidst Pull Back
LeEco Cutting Over 70% of Staff in U.S. Amidst Pull Back


Leave a Reply

© 2006-2018 Ticker Report. Google+.